Bertrand CHESNEAU

Dr. Bertrand CHESNEAU

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 February 2022 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
BCBertrand CHESNEAU
Bertrand CHESNEAU
MAMarion Aubert‐Mucca
Marion Aubert‐Mucca
FFFélix Fremont
Félix Fremont
JPJacmine Pechmeja
Jacmine Pechmeja
VSVincent Soler
Vincent Soler
JPJulie Plaisancié
Julie Plaisancié

10 March 2020 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
BCBertrand CHESNEAU
Bertrand CHESNEAU
TEThomas Edouard
Thomas Edouard
YDYves Dulac
Yves Dulac
HCHélène Colineaux
Hélène Colineaux
MLMaud Langeois
Maud Langeois
JPJulie Plaisancié
Julie Plaisancié
Background: Pathogenic SMAD3 variants are responsible for a cardiovascular phenotype, mainly thoracic aortic aneurysms and dissections. Precocious identification of the vascular risk such as aortic dilatation in mutated patients has a major impact in terms of management, particularly to avoid dissection and sudden death. These vascular damages are classically associated with premature osteoarthritis and skeletal abnormalities. However, variable expressivity and incomplete penetrance are common with SMAD3 variants.Methods: To investigate the clinical variability observed within SMAD3 patients, we reviewed the phenotypic and genetic data of 22 new patients from our Centre and of 133 patients reported in the literature. From this cohort of 155 mutated individuals, we first aimed to delineate an estimated frequency of the main clinical signs associated with SMAD3 pathogenic variants and, then, to look for genotype‐phenotype correlations, mainly to see if the aortic phenotype (AP) could be predicted by the SMAD3 variant type.Results: We showed, herein, the absence of correlation between the SMAD3 variant type and the occurrence of an AP in patients.Conclusion: Therefore, this report brings additional data for the genotype‐phenotype correlations of SMAD3 variants and the need to explore in more detail the effects of genetic modifiers that could influence the phenotype.

30 March 2026 in Nature Genetics
Verified
Journal Article
Open access
PDF file
ELElsa Leitão
Elsa Leitão
ASAmandine Santini
Amandine Santini
BCBenjamin Cogne
Benjamin Cogne
MEMiriam Essid
Miriam Essid
MAMaria Athanasiadou
Maria Athanasiadou
CNCaroline Nava
Caroline Nava
Small nuclear RNAs (snRNAs) are essential components of the spliceosome. De novo variants in snRNA genes RNU4-2 (ReNU syndrome), RNU5B-1 and RNU2-2 have been linked to dominant neurodevelopmental disorders (NDDs), revealing a large unexpected contribution of noncoding RNA genes to genetic diseases. Here, through international collaborations, we analyze systematically 200 potentially functional snRNA genes in a French cohort of 34,329 people with rare disorders. We report RNU2-2 variants in 141 individuals, including 35 with recurrent dominant pathogenic variants and 91 affected members from 73 families with biallelic variants. Recessive RNU2-2 NDD is at least twice as frequent as the dominant form and often involves a de novo variant in trans with an inherited allele, consistent with the high mutability of snRNA genes. Dominant and recessive RNU2-2 NDDs share overlapping clinical features, with frequent epilepsy. Blood transcriptomics and DNA methylation analyses revealed subtle, variant-specific effects on splicing and episignatures. Our results support a gradient-of-impact model bridging dominant and recessive inheritance, and establish RNU2-2 variants as a principal contributor to NDDs, nearly as prevalent as ReNU syndrome.

21 October 2021 in Molecular Genetics & Genomic Medicine
Verified
Journal Article
Open access
PDF file
BCBertrand CHESNEAU
Bertrand CHESNEAU
APAurélie Plancke
Aurélie Plancke
GRGuillaume Rolland
Guillaume Rolland
BMBertrand Marcheix
Bertrand Marcheix
YDYves Dulac
Yves Dulac
PKPhilippe Khau-Van-Kien
Philippe Khau-Van-Kien
Background: Pathogenic variants in MYH11 are associated with either heritable thoracic aortic aneurysm and dissection (HTAAD), patent ductus arteriosus (PDA) syndrome, or megacystis‐microcolon‐intestinal hypoperistalsis syndrome (MMIHS).Methods and Results: We report a family referred for molecular diagnosis with HTAAD/PDA phenotype in which we found a variant at a non‐conserved position of the 5’ donor splice site of intron 32 of MYH11 potentially altering splicing (NM_002474.3:c.4578+3A>C). Although its cosegregation with disease was observed, it remained of unknown significance. Later, aortic surgery in the proband gave us the opportunity to perform a transcript analysis. This showed a skipping of the exon 32, an RNA defect previously reported to be translated to an in‐frame loss of 71 amino acids and a dominant‐negative effect in the smooth muscle myosin rod. This RNA defect is also reported in 3 other HTAAD/PDA pedigrees.Conclusion: This report confirms that among rare variants in MYH11, skipping of exon 32 is recurrent. This finding is of particular interest to establish complex genotype–phenotype correlations where some alleles are associated with autosomal dominant HTAAD/PDA, while others result in recessive or dominant visceral myopathies.

7 January 2021 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
BCBertrand CHESNEAU
Bertrand CHESNEAU
APAurélie Plancke
Aurélie Plancke
GRGuillaume Rolland
Guillaume Rolland
NCNicolas Chassaing
Nicolas Chassaing
CCChristine Coubes
Christine Coubes
PKPhilippe Khau-Van-Kien
Philippe Khau-Van-Kien
Marfan syndrome (MFS) is a heritable connective tissue disorder (HCTD) caused by pathogenic variants in FBN1 that frequently occur de novo. Although individuals with somatogonadal mosaicisms have been reported with respect to MFS and other HCTD, the overall frequency of parental mosaicism in this pathology is unknown. In an attempt to estimate this frequency, we reviewed all the 333 patients with a disease-causing variant in FBN1. We then used direct sequencing, combined with High Resolution Melting Analysis, to detect mosaicism in their parents, complemented by NGS when a mosaicism was objectivized. We found that (1) the number of apparently de novo events is much higher than the classically admitted number (around 50% of patients and not 25% as expected for FBN1) and (2) around 5% of the FBN1 disease-causing variants were not actually de novo as anticipated, but inherited in a context of somatogonadal mosaicisms revealed in parents from three families. High Resolution Melting Analysis and NGS were more efficient at detecting and evaluating the level of mosaicism compared to direct Sanger sequencing. We also investigated individuals with a causal variant in another gene identified through our “aortic diseases genes” NGS panel and report, for the first time, on an individual with a somatogonadal mosaicism in COL5A1. Our study shows that parental mosaicism is not that rare in Marfan syndrome and should be investigated with appropriate methods given its implications in patient’s management.

Verified
Journal Article
Open access
PDF file
JPJulie Plaisancié
Julie Plaisancié
BCBertrand CHESNEAU
Bertrand CHESNEAU
LTLucas FARES TAIE
Lucas FARES TAIE
Jean-Michel RozetJean-Michel Rozet
Jean-Michel Rozet
JPJacmine Pechmeja
Jacmine Pechmeja
NCNicolas Chassaing
Nicolas Chassaing
Ocular malformations (OMs) arise from early defects during embryonic eye development. Despite the identification of over 100 genes linked to this heterogeneous group of disorders, the genetic cause remains unknown for half of the individuals following Whole-Exome Sequencing. Diagnosis procedures are further hampered by the difficulty of studying samples from clinically relevant tissue, which is one of the main obstacles in OMs. Whole-Genome Sequencing (WGS) to screen for non-coding regions and structural variants may unveil new diagnoses for OM individuals. In this study, we report a patient exhibiting a syndromic OM with a de novo 3.15 Mb inversion in the 6p25 region identified by WGS. This balanced structural variant was located 100 kb away from the FOXC1 gene, previously associated with ocular defects in the literature. We hypothesized that the inversion disrupts the topologically associating domain of FOXC1 and impairs the expression of the gene. Using a new type of samples to study transcripts, we were able to show that the patient presented monoallelic expression of FOXC1 in conjunctival cells, consistent with the abolition of the expression of the inverted allele. This report underscores the importance of investigating structural variants, even in non-coding regions, in individuals affected by ocular malformations.